Press "Enter" to skip to content

New patent for Pfizer drug IBRANCE

0
Copyright © DrugPatentWatch. Originally published at New patent for Pfizer drug IBRANCE

Annual Drug Patent Expirations for IBRANCE
Annual Drug Patent Expirations for IBRANCE

Ibrance is a drug marketed by Pfizer and is included in two NDAs. It is available from three suppliers. There are five patents protecting this drug and one Paragraph IV challenge.

Drug patent litigation for IBRANCE.

This drug has one hundred and six patent family members in fifty-four countries.

The generic ingredient in IBRANCE is palbociclib. Three suppliers are listed for this compound. Additional details are available on the palbociclib profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at New patent for Pfizer drug IBRANCE
Find your next blockbuster

Get accurate and timely intelligence — in just a few clicks

✓ Free trial

✓ No credit card

 

DrugPatentWatch - Make Better Decisions